Literature DB >> 9063443

Differential interaction of bile acids from patients with inborn errors of bile acid synthesis with hepatocellular bile acid transporters.

B Stieger1, J Zhang, B O'Neill, J Sjövall, P J Meier.   

Abstract

People with genetic or acquired defects in the biosynthesis of bile acids may suffer from cholestasis. Patients with a deficiency of 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase/isomerase from 3 beta, 7 alpha-dihydroxy- and 3 beta, 7 alpha, 12 alpha-trihydroxy-5-cholenoic acids, the sulfated and partially glycine-conjugated forms of which are found in their urine and bile. 3-Oxo-delta 4 bile acids are detected in the urine of patients with a deficiency of 5 beta-reductase. It has been postulated that these unusual bile acids might act as cholestatic agents in these patients. The aim of the present study was to test this hypothesis in an in vitro system, since the abnormal bile acids would be metabolized in in vivo experiments. Basolateral (sinusoidal) and canalicular plasma membrane vesicles were isolated from rat liver. A rapid filtration method was used to determine transport of cholyltaurine in the presence of model bile acids into the isolated vesicles. It was found that 3 beta, 7 alpha-dihydroxy-5-cholenoic acid and 7 alpha-hydroxy-3-oxo-4-cholenoic acid both inhibited the apical, ATP-dependent transport system for cholyltaurine in a competitive manner with K(m) values of 15 microM and 16 microM, respectively. Radioactively labeled 3 beta, 7 alpha-dihydroxy-5-cholenoyltaurine and 7 alpha-hydroxy-3-oxo-4-cholenoyltaurine were not transported by the same transport system. The same types of experiments were performed with basolateral plasma membrane vesicles. It was found that, in contrast to the canalicular ATP-dependent bile acid transport system, only 7 alpha-hydroxy-3-oxo-4-cholenoyltaurine was a competitive inhibitor of the sodium-dependent transport system for cholyltaurine with a K(m) of 16 microM. Studies with radioactively labeled 7 alpha-hydroxy-3-oxo-4-cholenoyltaurine and 3 beta, 7 alpha-dihydroxy-5-cholenoyltaurine revealed that 7 alpha-hydroxy-3-oxo-4-cholenoyltaurine was transported in a sodium-dependent manner into basolateral rat liver plasma membrane vesicles, whereas 3 beta, 7 alpha-dihydroxy-5-cholenoyltaurine was not transported in a sodium-dependent way. These results support the hypothesis that the unusual bile acids found in patients with defects in bile acid biosynthesis might act as cholestatic agents by inhibiting the canalicular ATP-dependent transport system for bile acids which constitutes the rate-limiting step in the overall process of bile acid transport across hepatocytes. Furthermore, the experiments demonstrated that, despite similar substrate specificities, the basolateral sodium-dependent and the apical ATP-dependent transport system for cholyltaurine might have different recognition sites for bile acids.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9063443     DOI: 10.1111/j.1432-1033.1997.00039.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  13 in total

Review 1.  The molecular genetics of familial intrahepatic cholestasis.

Authors:  P L Jansen; M Müller
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

Review 2.  Planar bile acids in health and disease.

Authors:  Stephanie J Shiffka; Maureen A Kane; Peter W Swaan
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-09-06       Impact factor: 3.747

3.  Fifty years with bile acids and steroids in health and disease.

Authors:  Jan Sjövall
Journal:  Lipids       Date:  2004-08       Impact factor: 1.880

4.  Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology.

Authors:  Vered Molho-Pessach; Jonathan J Rios; Chao Xing; Kenneth D R Setchell; Jonathan C Cohen; Helen H Hobbs
Journal:  Hepatology       Date:  2012-02-08       Impact factor: 17.425

Review 5.  Bile acids: chemistry, physiology, and pathophysiology.

Authors:  Maria J Monte; Jose J G Marin; Alvaro Antelo; Jose Vazquez-Tato
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

6.  Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy.

Authors:  H A Lemonde; E J Custard; J Bouquet; M Duran; H Overmars; P J Scambler; P T Clayton
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7alpha-hydroxylase gene causes severe neonatal liver disease.

Authors:  K D Setchell; M Schwarz; N C O'Connell; E G Lund; D L Davis; R Lathe; H R Thompson; R Weslie Tyson; R J Sokol; D W Russell
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 8.  Mechanisms of disease: Inborn errors of bile acid synthesis.

Authors:  Shikha S Sundaram; Kevin E Bove; Mark A Lovell; Ronald J Sokol
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-06-24

9.  Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders.

Authors:  James E Heubi; Kevin E Bove; Kenneth D R Setchell
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-09       Impact factor: 2.839

10.  Cholic acid therapy in Zellweger spectrum disorders.

Authors:  Kevin Berendse; Femke C C Klouwer; Bart G P Koot; Elles M Kemper; Sacha Ferdinandusse; Kiran V K Koelfat; Martin Lenicek; Frank G Schaap; Hans R Waterham; Frédéric M Vaz; Marc Engelen; Peter L M Jansen; Ronald J A Wanders; Bwee Tien Poll-The
Journal:  J Inherit Metab Dis       Date:  2016-07-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.